Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aerovate Therapeutics Inc | AVTE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 21.57 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 21.57 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.41 - 32.415 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 21.57 | USD |
Aerovate Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 596.82M | 27.67M | - | 0 | -75.52M | -2.73 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aerovate Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVTE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 21.16 | 23.9764 | 19.83 | 21.91 | 180,148 | 0.41 | 1.94% |
| 1 Month | 30.43 | 32.415 | 19.83 | 25.34 | 174,298 | -8.86 | -29.12% |
| 3 Months | 18.27 | 32.415 | 16.74 | 24.75 | 147,916 | 3.30 | 18.06% |
| 6 Months | 9.80 | 32.415 | 9.41 | 21.68 | 115,407 | 11.77 | 120.10% |
| 1 Year | 18.74 | 32.415 | 9.41 | 19.29 | 97,438 | 2.83 | 15.10% |
| 3 Years | 28.00 | 32.415 | 7.74 | 18.56 | 98,531 | -6.43 | -22.96% |
| 5 Years | 28.00 | 32.415 | 7.74 | 18.56 | 98,531 | -6.43 | -22.96% |
Aerovate Therapeutics Description
| Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. |
